Shares of Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) have been given an average rating of “Buy” by the ten analysts that are covering the firm, Marketbeat.com reports. Ten equities research analysts have rated the stock with a buy rating. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.88.
A number of research analysts have recently weighed in on the company. Zacks Investment Research upgraded Infinity Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.75 price objective for the company in a research report on Wednesday. HC Wainwright restated a “buy” rating and set a $9.00 price objective on shares of Infinity Pharmaceuticals in a research report on Monday, December 13th.
Shares of INFI opened at $1.51 on Friday. Infinity Pharmaceuticals has a 1 year low of $1.48 and a 1 year high of $5.98. The firm has a market cap of $134.41 million, a PE ratio of -2.65 and a beta of 1.93. The stock’s fifty day moving average price is $2.34 and its two-hundred day moving average price is $2.78.
Infinity Pharmaceuticals (NASDAQ:INFI) last issued its quarterly earnings results on Tuesday, November 2nd. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.14) by $0.02. Infinity Pharmaceuticals had a negative return on equity of 172.12% and a negative net margin of 2,398.81%. The business had revenue of $0.43 million during the quarter, compared to analyst estimates of $0.45 million. During the same quarter in the prior year, the business posted ($0.16) EPS. On average, equities analysts forecast that Infinity Pharmaceuticals will post -0.53 EPS for the current year.
This guide will help you identify and execute an options trading strategy that fits your specific needs and risk profile.
Take your trading to the next level with the Options Strategy Guide.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. IFP Advisors Inc bought a new stake in Infinity Pharmaceuticals in the third quarter worth about $27,000. Legal & General Group Plc bought a new stake in Infinity Pharmaceuticals in the second quarter worth about $27,000. Tradewinds Capital Management LLC bought a new stake in Infinity Pharmaceuticals in the third quarter worth about $34,000. Citigroup Inc. lifted its stake in Infinity Pharmaceuticals by 141.7% in the third quarter. Citigroup Inc. now owns 10,073 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 5,906 shares during the last quarter. Finally, Parametric Portfolio Associates LLC bought a new stake in Infinity Pharmaceuticals in the second quarter worth about $31,000. Institutional investors own 55.14% of the company’s stock.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.
Read More: How Do Mutual Funds Work?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected]
Before you consider Infinity Pharmaceuticals, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Infinity Pharmaceuticals wasn’t on the list.
While Infinity Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.